Objective:
To summarize current and emerging treatments for geographic atrophy (GA) associated with age-related macular degeneration (AMD) and their implications for patient care.
Key Findings:
- GA accounts for approximately 20% of legal blindness in the US, with a median progression time to blindness of 6.2 years.
- Current treatments slow GA progression but do not prevent or reverse it.
- Photobiomodulation therapy shows promise in improving visual acuity and reducing GA development.
- Pegcetacoplan and avacincaptad pegol have demonstrated significant efficacy in reducing GA lesion growth in clinical trials.
Interpretation:
The advancements in GA treatments represent a significant step forward in managing a condition that leads to blindness, with ongoing research promising further innovations.
Limitations:
- Current treatments do not prevent or reverse GA.
- Limited options available compared to treatments for neovascular AMD.
Conclusion:
The landscape of GA treatment is evolving, with new therapies offering hope for slowing progression and improving patient outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.